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The impact of novel drugs for treating multiple myeloma (MM) on the utilization and outcomes of autologous
hematopoietic progenitor cell transplantation (AHPCT) is unknown. We reviewed characteristics and
outcomes of 20,278 patients who underwent AHPCT within 12 months of diagnosis of MM in the United
States and Canada and registered at the Center for International Blood and Marrow Transplant Research
(CIBMTR) in 3 time cohorts reﬂecting the increasing availability of novel drugs: 1995 to 1999 (n ¼ 2226), 2000
to 2004 (n ¼ 6408), and 2005 to 2010 (n ¼ 11,644). In the United States, the number of AHPCTs performed
increased at a greater rate than new MM cases. Patients in recent cohorts were older, less likely to have stage
3 MM, and more likely to have received previous thalidomide, lenalidomide, or bortezomib. On multivariate
analysis, AHPCT in the 2000 to 2004 cohort (HR ¼ 0.77) or in the 2005 to 2010 cohort (HR ¼ 0.68) were
associated with lower risk of death. Survival at 60 months post-AHPCT improved from 47% in 1995 to 1999 to
55% in 2000 to 2004 and to 57% in 2005 to 2010, owing less to improvement in progression-free survival (50%
versus 55% versus 57% at 24 months) than to postrelapse/progression survival (58% versus 65% versus 72% at
24 months). AHPCT and new biological agents are complementary, nonredundant therapies and should be
combined in the management of MM in suitable patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
The last 2 decades have brought improved survival of
patients diagnosed with multiple myeloma (MM), as veriﬁed
by population-based studies [1-6]. Numerous factors have
contributed to this improvement, including better sup-
portive care, greater access to hematopoietic progenitor cell54th Annual Meeting of the American
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13.08.002transplantation, and availability of new drugs. The relative
contributions of these factors are mostly unknown.
Autologous hematopoietic progenitor cell transplantation
(AHPCT) is an important component of the early manage-
ment of MM in younger patients. More recently, AHPCT has
been extended to older patients [7,8] and patients with
comorbidities.
Most epidemiologic studies suggest much greater recent
improvement in survival of patients age <60 to 65 years,
with little or no improvement in older patients. The era of
greatest improvement has been identiﬁed as the mid-1990s
and early 2000s, coinciding with broader use of AHPCT
[2,4,6]. More recent studies have reported further gains in
survival in the late 2000s [3,5].Transplantation.
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lenalidomide in induction therapy has led to rates of remis-
sion and complete remission previously obtainable only with
AHPCT [9-13]. If and how the success of conventional therapy
has affected the use of AHPCT in the early management
of MM in the United States and the outcomes of MM
patients undergoing early AHPCT in the United States and
Canada remains unknown.
Here we describe the use of AHPCT early (in the ﬁrst
12 months) in the course of therapy for MM in 1995 to 1999
(before the availability of thalidomide), 2000 to 2004 (after
the availability of thalidomide), and 2005 to 2010 (after the
availability of thalidomide, bortezomib, and lenalidomide).
We compared survival in these 3 cohorts as an indication of
the impact of these novel drugs in patients undergoing early
AHPCT to treat MM.
PATIENTS AND METHODS
Patients
Recipients of a ﬁrst AHPCT for MM in the United States and Canada
between 1995 and 2010 registered with the CIBMTR were included in this
study. The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplant Registry and the National Marrow Donor Program (NMDP).
Established in 2004, it receives data from >500 transplantation centers
worldwide on AHPCT and allogeneic hematopoietic progenitor cell trans-
plantation (HCPT). Data are submitted to the Statistical Center at theMedical
College of Wisconsin in Milwaukee and the NMDP Coordinating Center in
Minneapolis, where computerized checks for discrepancies, physicians’
review of submitted data, and onsite audits of participating centers ensure
data quality.
The CIBMTR collects both Transplant Essential Data (TED) and
Comprehensive Report Form (CRF) data before transplantation,100 days and
6months after transplantation, and annually thereafter. Of relevance for this
study, the TED database captures demographic information, disease isotype
and stage, date of diagnosis, disease status at transplantation (response to
previous therapy), date of transplantation, and conditioning regimen. The
pretransplantation CRF database captures additional information, such as
chromosomal abnormalities present at diagnosis, treatment regimen(s)
used before transplantation, and supportive care measures. Post-
transplantation CRF data include response to AHPCT and additional
therapy administered, either as maintenance or to treat progressive or
relapsed disease.
Disease staging for MM followed the Durie-Salmon Staging System
(DSS) [14] and/or the International Staging System (ISS) [15]. The DSS and
ISS are not equivalent, as demonstrated speciﬁcally in patients undergoing
AHPCT [16]. Owing to its long time span, the present study captures the
transition from the predominant use of DSS to the use of ISS, and not a single
staging system is available for the majority of cases. Given the similar
survival in patients with MM in DSS stage III and ISS stage III undergoing
AHPCT [16], our analysis used the presence of DSS or ISS stage III. Response
assessment followed European Group for Blood and Marrow Trans-
plantation criteria [17] and, in more recent years, the international uniform
response criteria for MM [18].
All observational studies conducted by the CIBMTR are performed with
approval of the Institutional Review Boards of the NMDP and the Medical
College of Wisconsin.
Statistics
Patient-, disease-, and transplantation-related variables in recipients of
ﬁrst AHPCT for MM were analyzed in 3 cohorts based on year of trans-
plantation: 1995 to 1999, 2000 to 2004, and 2005 to 2010. Only patients
with 100 days of follow-up were included. Cohorts were compared using
the c2 test for categorical variables and the Kruskal-Wallis test for contin-
uous variables.
The estimated numbers of ﬁrst AHPCTs for MM performed in the United
States at any time andwithin 12months of diagnosis (ie, early therapy) were
calculated for each cohort and age group by multiplying the number of
AHPCTs registered with the CIBMTR by a correction factor, accounting for
the fact that a known proportion of AHPCT procedures are registered at
CIBMTR (methodology described elsewhere [19]). For the purpose of
comparison, each cohort was divided into 3 age groups: <50 years, 50 to
64 years, and 65 years. Owing to possible imprecision in the correction
factor, the numbers of procedures are displayed with a10%margin of error.
The total number of newly diagnosed MM cases in United States was
calculated for the different cohorts and age groups of interest using agegroupe and period-speciﬁc incidence rates from the Surveillance Epide-
miology and End Results (SEER)-13 database [20] (using SEERstat version
7.0.9), the total US population estimated or counted for each period, and
speciﬁc age strata using data fron the US Census Bureau [21]. Given that
incidence rate was not available for 2010, numbers of MM cases and AHPCT
procedures were calculated for 2005 to 2009 instead of 2005 to 2010 in the
most recent cohort. Because the SEER database includes only the United
States, patients from Canada were excluded from the utilization analysis.
Probabilities of overall survival (OS) and progression-free survival (PFS)
were calculated using the Kaplan-Meier estimator with the variance esti-
mated by Greenwood formula. Potential prognostic factors for survival were
evaluated in a multivariate analysis using Cox proportional hazards
regression. Variables considered in multivariate analysis were age at
transplantation, sex, disease stage, Karnofsky performance scale (KPS) score,
numbers of lines of previous therapy, sensitivity to induction therapy, time
from diagnosis to transplantation, and time cohort of transplantation. A line
of therapy was deﬁned as 1 or more cycles of a deﬁned treatment program
with no progression of disease in between. A new line of therapy started
when a newagentwas added or changed owing to relapse, progression, and/
or toxicity, or after a period of observationwhen a new agent was started for
progression or relapse. A stepwise model selection approach at a signiﬁ-
cance level of P < .05 was used to identify all signiﬁcant risk factors. Each
step of model building contained the main effect for the transplantation
period (1994 to 1999 versus 2000 to 2004 versus 2005 to 2010). In the
model, the assumption of proportional hazards was tested for each variable.
All variables considered in the multivariate analysis satisﬁed the
proportionality assumption. Potential interactions between the main effect
and all other signiﬁcant risk factors were tested. Adjusted survival proba-
bilities were generated from the ﬁnal Cox models. All statistical analyses
were performed with SAS version 9 (SAS Institute, Cary, NC). All P values are
2-sided.
RESULTS
AHPCT Utilization in the United States
A total of 23,725 ﬁrst AHPCTs for MM in the United States
were registered at the CIBMTR between 1995 and 2009.
Based on this number, we estimated a total of 32,151 ﬁrst
AHPCTs, of which 21,960 (68.3%) were performed within
12 months of diagnosis, corresponding to 13.4% and 9.2%,
respectively, of the estimated 238,235 MM cases diagnosed
in the United States between 1995 and 2009.
Over the 3 periods (1994 to 1999, 2000 to 2004, 2005 to
2009), there was an increased volume of AHPCTs during the
ﬁrst 12 months after diagnosis at a rate exceeding the
increase in new MM cases (Figure 1) in all age categories
(<50, 50 to 64, and 65 years).
Patient Characteristics
Between 1995 and 2010, a total of 29,489 ﬁrst AHPCTs
performed in the United States (91%) and Canada (9%),
including 20,278 AHPCTs performed within the ﬁrst
12 months after diagnosis, were registered at the CIBMTR
using TED forms (Table 1). More complete patient-, disease-,
and transplantation-related data were available for 4373
patients who underwent AHPCT as early therapy and were
reported to the CIBMTR using comprehensive CRFs (Table 2).
Because of delays in data reporting, there are a dispropor-
tionally low number of AHPCT cases in 2009 and 2010 in the
CRF dataset, but not in the TED dataset.
The age of AHPCT recipients increased across the 3 study
periods (median age, 54, 57, and 59 years, respectively), with
a marked increase in the proportion of patients age
65 years (8% versus 19% versus 24%). The proportion of
AHPCTs was relatively lower in African-American patients,
with no substantial change over time (Table 1).
Disease and Induction Characteristics
Characteristics of patients receiving AHPCTas early therapy
in the 3 cohorts are displayed in Table 2. As expected, there
were stepwise increases in the use of thalidomide (<1% versus
Figure 1. Changes in the estimated number of patients who underwent ﬁrst AHPCT to treat MM with time and by age group. Error bars represent 10%. The sharp
increase in the number of AHPCTs performed contrasts with the much slower rate of increase in the number of newly diagnosed cases of MM.
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and bortezomib (0% versus 2% versus 35%) for pre-
transplantation induction therapy across the 3 cohorts.Table 1
Characteristics of PatientsWho Underwent First AHPCT for MM in the United States
Time Cohort
Characteristic All First Transplanta
1995-1999 2000
Number of patients 3745 9082
Number of centers 197 202
Age at transplantation, yr, median (range) 54 (19-78) 57
Age at transplantation, yr, n (%)
<50 1159 (31) 1897
50-64 2302 (61) 5466
65 284 (8) 1719
Sex, n (%)
Male 2184 (58) 5380
Female 1561 (42) 3702
KPS score before transplantation, n (%)
80 333 (9) 5947
<80 27 (<1) 416
Missing 3385 (90) 2719
Conditioning regimen, n (%)
Melphalan alone 1753 (50) 7038
Melphalan þ TBI  others 796 (23) 254
Busulfan þ cyclophosphamide  others 673 (19) 333
Othersd 263 (8) 209
Time from diagnosis to transplantation, mo, median (range) 9 (<1-249) 8
<6 610 (16) 2219
6-12 1619 (43) 4191
12-24 657 (18) 1317
24-36 266 (7) 444
>36 348 (9) 627
Missing 245 (7) 284
Type of transplantation, n (%)
Single 3121 (83) 7215
Double, interval between transplantations <6 mo 262 (7) 651
Double, interval between transplantations >6 mo 362 (10) 1216
Yr of transplantation, n (%)
1995 366 (10) d
1996 532 (14) d
1997 768 (21) d
1998 950 (25) d
1999 1129 (30) d
2000 d 1330
2001 d 1642
2002 d 1817
2003 d 1995
2004 d 2298
2005 d d
2006 d d
2007 d d
2008 d d
2009 d d
2010 d d
Follow-up for survivors, mo, median (range) 122 (3-194) 74Simultaneously, there were marked decreases in the use of
melphalan and prednisone and of vincristine, doxorubicin,
and dexamethasone. There was an increase in the proportionsand Canada Registered with the CIBMTR (TED Dataset) from 1995 to 2010, by
tions Early (<12 Mo) Transplantations
-2004 2005-2010 1995-1999 2000-2004 2005-2010
16,662 2226 6408 11,644
177 189 195 174
(19-80) 59 (18-89) 54 (19-77) 57 (22-80) 58 (18-89)
(21) 2803 (17) 734 (33) 1445 (23) 2079 (18)
(60) 9885 (59) 1330 (60) 3875 (61) 6945 (60)
(19) 3974 (24) 162 (7) 1088 (17) 2620 (23)
(59) 9788 (59) 1313 (59) 3783 (59) 6905 (59)
(41) 6878 (41) 913 (41) 2626 (41) 4739 (41)
(65) 12068 (72) 230 (10) 4336 (68) 8419 (72)
(5) 1234 (7) 15 (<1) 302 (5) 842 (7)
(30) 3360 (20) 1981 (89) 1770 (28) 2383 (20)
(90) 15675 (98) 1057 (49) 5048 (90) 10,997 (99)
(3) 19 (<1) 513 (24) 184 (3) 9 (<1)
(4) 162 (1) 430 (20) 223 (4) 111 (1)
(3) 87 (<1) 143 (7) 146 (3) 47 (<1)
(<1-255) 8 (<1-359) 9 (<1-12) 8 (<1-12) 8 (<1-12)
(24) 3927 (24) 609 (27) 2218 (35) 3927 (34)
(46) 7717 (46) 1617 (73) 4190 (65) 7717 (66)
(15) 2898 (17) d d d
(5) 867 (5) d d d
(7) 1137 (7) d d d
(3) 116 (<1) d d d
(79) 13,659 (82) 1813 (82) 4922 (77) 9338 (80)
(7) 1812 (11) 180 (8) 548 (9) 1413 (12)
(13) 1191 (7) 233 (10) 938 (15) 893 (8)
d 178 (8) d d
d 308 (14) d d
d 459 (21) d d
d 578 (26) d d
d 705 (32) d d
(15) d d 860 (13) d
(18) d d 1165 (18) d
(20) d d 1286 (20) d
(22) d d 1451 (23) d
(25) d d 1646 (26) d
2517 (15) d d 1786 (15)
2650 (16) d d 1878 (16)
2438 (15) d d 1731 (15)
2593 (16) d d 1760 (15)
3106 (19) d d 2146 (18)
3358 (20) d d 2343 (20)
(3-139) 25 (3-79) 125 (3-194) 74 (3-139) 25 (3-79)
Table 2
Characteristics of Patients Who Underwent First AHPCT Within 12 Months of Diagnosis for MM in the United States and Canada, Reported to the CIBMTR
between 1995 and 2010 (CRF Dataset), by Time Cohort
Characteristic 1995-1999 2000-2004 2005-2010 P Value
Number of patients 686 1464 2223
Number of centers 114 126 114
Demographic data
Age at AHPCT, yr, median (range) 54 (27-73) 57 (22-80) 57 (22-80)
Age at AHPCT, yr, n (%)
<50 222 (32) 309 (21) 473 (21) <.001
50-64 412 (60) 864 (59) 1322 (59)
65 52 (7) 291 (20) 428 (20)
Sex, n (%)
Male 422 (62) 877 (60) 1322 (59) .633
Female 264 (38) 587 (40) 901 (41)
Race, n (%)
Caucasian 550 (80) 1153 (79) 1726 (78) .019
African American 96 (14) 190 (13) 332 (15)
Hispanic 28 (4) 53 (4) 103 (5)
Others* 10 (1) 53 (3) 52 (2)
Missing 2 (<1) 15 (1) 10 (<1)
KPS score before AHPCT, n (%)
80 624 (91) 1274 (87) 1883 (85) <.001
<80 58 (8) 121 (8) 165 (7)
Missing 4 (<1) 69 (5) 175 (8)
Disease-related
Immunochemical subtype of myeloma, n (%)
IgG 371 (54) 753 (51) 1228 (55) <.001
IgA 125 (18) 266 (18) 440 (20)
Light chain 116 (17) 271 (19) 396 (18)
Nonsecretory 37 (5) 69 (5) 72 (3)
Othersy 5 (<1) 16 (1) 34 (2)
Missing 32 (5) 89 (6) 53 (2)
DSS stage at diagnosis, n (%)
Stage I 55 (8) 93 (6) 84 (4)
Stage II 179 (26) 403 (28) 291 (13)
Stage III 421 (61) 890 (61) 749 (34)
Missing 31 (5) 78 (5) 1099 (49)
ISS stage at diagnosis, n (%)
Stage I 127 (19) 279 (19) 501 (23)
Stage II 149 (22) 271 (19) 512 (23)
Stage III 87 (13) 177 (12) 353 (16)
Missing 323 (47) 737 (50) 857 (39)
DSS/ISS stage III at diagnosis, n (%)
Yes 441 (64) 936 (64) 975 (44) <.001
No 224 (33) 469 (32) 914 (41)
Missing 21 (3) 59 (4) 334 (15)
Treatment-related
Lines of chemotherapy before AHPCT, n (%)
1 477 (70) 921 (63) 1410 (63) <.001
>1 206 (30) 527 (36) 751 (34)
Missing 3 (<1) 16 (1) 67 (3)
Therapy before AHPCT, n (%)z
Melphalan and prednisone  others 109 (16) 70 (5) 14 (<1) <.001
Vincristine, doxorubicin, and dexamethasone  others 549 (80) 967 (66) 244 (11) <.001
Thalidomide  others 3 (<1) 322 (22) 1163 (52) <.001
Bortezomib  others 0 (0) 34 (2) 782 (35) <.001
Lenalidomide  others 0 (0) 4 (<1) 465 (21) <.001
Thalidomide þ bortezomib  others 0 (0) 23 (2) 359 (16) <.001
Lenalidomide þ bortezomib  others 0 (0) 0 (<1) 173 (7) <.001
Missing 3 (<1) 16 (1) 62 (3) <.001
Sensitivity to therapy, n (%)
Sensitive 539 (79) 1273 (87) 1966 (88) <.001
Resistant 147 (21) 182 (12) 215 (10)
Missing 0 (0) 9 (<1) 42 (2)
Disease status before AHPCT, n (%)
Complete/partial remission 539 (79) 1273 (87) 1966 (88) <.001
Minimal Response/ No Response/ Stable Disease 124 (18) 177 (12) 179 (8)
Relapse/progression 23 (3) 5 (<1) 36 (2)
Missing 0 (0) 11 (<1) 46 (2)
Conditioning regimen, n (%)
Melphalan alone 370 (54) 1363 (93) 2198 (99) <.001
Melphalan þ TBI  others 155 (23) 35 (2) 4 (<1)
Busfulan þ cyclophosphamide  others 120 (17) 44 (3) 19 (<1)
Othersx 41 (6) 22 (2) 2 (<1)
CD34  106/kg, median (range) 4 (0.8-61) 5 (0.7-98) 5 (0.8-102)
Evaluable, n (%) 590 (86) 1348 (91) 2176 (97)
(continued on next page)
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Table 2
(continued)
Characteristic 1995-1999 2000-2004 2005-2010 P Value
Time of diagnosis, mo, median (range) 7 (2-12) 7 (2-12) 7 (<1-12)
Diagnosis at <6 mo, n (%) 207 (30) 457 (31) 724 (33) .435
Diagnosis at >6 mo, n (%) 479 (70) 1007 (69) 1499 (67)
Type of HCT, n (%)
Single 528 (77) 1024 (70) 1416 (64) <.001
Tandem, planned second AHPCT 93 (14) 190 (13) 461 (21)
Tandem, planned second allogeneic HPCT 1 (<1) 66 (5) 164 (7)
Tandem, no planned second AHPCT 64 (9) 184 (13) 182 (8)
Mobilization, n (%)
Granulocyte colony-stimulating factor alone 167 (24) 358 (24) 921 (41) <.001
Chemotherapy þ granulocyte colony-stimulating factor 508 (74) 1083 (74) 1264 (57)
Missing 11 (2) 23 (2) 38 (2)
Use of plerixafor, n (%)
Yes 0 (0) 8 (<1) 55 (2) <.001
No 675 (98) 1433 (98) 2130 (96)
Missing 11 (2) 23 (2) 38 (2)
Interval between ﬁrst and second HCT, mo, median (range) 6 (<1-176) 5 (1-122) 4 (1-75)
Interval between ﬁrst and second HCT, mo, n (%)
<6 80 (51) 233 (50) 607 (72) <.001
6-12 18 (11) 37 (9) 43 (6)
12-24 9 (6) 27 (6) 46 (6)
>24 51 (32) 143 (34) 111 (16)
Reported maintenance therapy post-AHPCT, n (%)z
None 367 (54) 1007 (69) 1626 (73) <.001
IFN-a 186 (27) 40 (3) 4 (<1) <.001
Steroid 36 (5) 165 (11) 258 (12) <.001
Thalidomide 35 (5) 221 (15) 252 (11) <.001
Bortezomib 4 (<1) 20 (1) 55 (2) <.001
Lenalidomide 0 (0) 6 (<1) 225 (10) <.001
IL-2 19 (3) 8 (<1) 0 (0) <.001
Cyclophosphmide 23 (3) 5 (<1) 5 (<1) <.001
Othersk 130 (19) 151 (10) 163 (7) <.001
Missing 5 (<1) 10 (<1) 0 (0) <.001
Yr of AHPCT, n (%)
1995 49 (7) d d
1996 90 (13) d d
1997 186 (27) d d
1998 173 (25) d d
1999 188 (27) d d
2000 d 213 (14) d
2001 d 314 (21) d
2002 d 292 (20) d
2003 d 218 (15) d
2004 d 427 (30) d
2005 d d 547 (25)
2006 d d 531 (24)
2007 d d 318 (14)
2008 d d 579 (26)
2009 d d 169 (8)
2010 d d 79 (4)
Follow-up of survivors, mo, median (range) 133 (3-176) 74 (3-122) 37 (3-75)
The follow-up complete index as of June 31, 2011, was 97% at 1 year, 91% at 3 years, and 85% at 5 years.
* Other races include the following:1995-1999: Asian and Paciﬁc Islander (n¼ 9) and Native American (n¼ 1); 2000-2004: Asian and Paciﬁc Islander (n¼ 41),
Native American (n ¼ 7), and Middle East white (n ¼ 5); 2005-2010: Asian and Paciﬁc Islander (n¼ 34), Native American (n ¼ 9), and Middle East white (n¼ 9).
y Other immunochemical subtypes of myeloma include the following:1995-1999: IgD (n ¼ 4), IgE (n ¼ 0), and IgM (n ¼ 1); 2000-2004: IgD (n ¼ 13), IgE
(n ¼ 0), and IgM (n ¼ 3); 2005-2010: IgD (n ¼ 23), IgE (n ¼ 3), and IgM (n ¼ 8).
z Patients receiving combinations of multiple drugs can be counted in more than 1 category, so the sum of percentages is not equal to 100%.
x Other conditioning regimens include the following:1995-1999: TBI  others (no melphalan) (n ¼ 26), busulfan (n ¼ 4), busulfan þ thiotepa (n ¼ 1),
cyclophosphamide (n¼ 1), cyclophosphamideþ etoposide (n¼ 3), cyclophosphamideþ etoposideþ nitrosurea (n¼ 3), cyclophosphamideþ etoposideþ thiotepa
(n ¼ 1), thiotepa (n ¼ 1), and cyclophosphamide þ taxol (n ¼ 1); 2000-2004: TBI  others (no melphalan) (n ¼ 9), corticosteroids (n ¼ 1), cyclophosphamide
(n ¼ 10), cyclophosphamide þ etoposide (n ¼ 1), cyclophosphamide þ etoposide þ nitro (n ¼ 1), and cyclophosphamide þ etoposide þ thiotepa (n ¼ 1); 2005-
2010: cyclophosphamide (n ¼ 1) and cyclophosphamide þ etoposide þ nitro (n ¼ 1).
k Other maintenance therapy includes the following:1995-1999: carmustine (n ¼ 2), cisplatin (n ¼ 16), clarithromycin (n ¼ 1), etoposide (n ¼ 13), melphalan
(n¼ 1), rituximab (n¼ 1), or vincristine (n¼ 2); 2000-2004: cisplatin (n¼ 1), clarithromycin (n¼ 1), melphalan (n¼ 7), rituximab (n¼ 2), or vincristine (n¼ 2);
2005-2010: carmustine (n ¼ 1). clarithromycin (n ¼ 7), doxorubicin (n ¼ 3), etoposide (n ¼ 1), melphalan (n ¼ 9), rituximab (n ¼ 1), or vincristine (n ¼ 2).
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in partial remission or better (Table 2).
Transplantation Characteristics
Melphalan alone was used for conditioning in approxi-
mately one half of AHPCTs in 1995 to 1999 and in almost allAHPCTs performed in 2005 to 2010. Consequently, there was
near disappearance of the use of total body irradiation (TBI)-
based and multidrug conditioning regimens. The vast
majority of patients in all 3 cohorts underwent a single
AHPCT. A planned tandem AHPCT was performed in 14% of
the patients in the 1995 to 1999 cohort, in 13% of the 2000 to
L.J. Costa et al. / Biol Blood Marrow Transplant 19 (2013) 1615e162416202004 cohort, and in 21% of the 2005 to 2010 cohort in the CRF
dataset. The proportion of AHPCT plus allogeneic tandem
HPCT also increased across time, from <1% to 5% to 7%.
Of interest, there was a marked reduction in use of some
types of maintenance therapy post-AHPCT over time, from
46% in the ﬁrst cohort to 27% in the third cohort. INF was the
most frequently used maintenance strategy in 1995 to 1999,
but was substantially less common in the later cohorts. There
was increase in use of immunomodulatory drugs post-
AHPCT, with thalidomide use peaking in the 2000 to 2004
cohort and lenalidomide use increased in the 2005 to 2010
cohort.
Survival
Median follow-up of survivors was 125 months (range, 3
to 194 months) for the 1995 to 1999 cohort, 74 months
(range, 3 to 139 months) for the 2000 to 2004 cohort, and
25 months (range, 3 to 79 months) for the 2005 to 2010
cohort. Survival increased across the 3 study periods in
patients who underwent AHPCT within 12 months, veriﬁed
with similar magnitude in both the CRF dataset and the
larger TED dataset (Figure 2 and Table 3). Adjusted survival
rates at 24, 48, and 60 months were superior in the 2000 to
2004 cohort (79%, 61%, and 53%, respectively) and the 2005
to 2010 cohort (84%, 65%, and 56%, respectively) compared
with the 1995 to 1999 cohort (72%, 54%, and 47%, respec-
tively) in the TED dataset. Similar survival rates were veriﬁed
for patients in the CRF dataset, conﬁrming that the CRF
dataset is a balanced sample of the TED dataset. There wereFigure 2. Outcomes of patients undergoing early (<12 months) AHPCT for MM in the 3
Survival for patients with more detailed information (CRF dataset). (C) PFS after tran
dataset. Comparisons across cohorts are presented in Table 3.also signiﬁcant differences between the 2000 to 2004 and
2005 to 2010 cohorts at 24 and 48 months in both datasets
and at 60 months in the TED dataset (Table 3). Of note, the
survival improvement over time beneﬁted patients in all 3
age groups (Figure 3).
To account for differences in patients in the 3 time
cohorts, we performed a multivariate analysis for OS using
the population with comprehensive data reported to the
CIBMTR (CRF dataset). Covariables analyzed included age,
sex, stage at diagnosis (DSS/ISS stage III), KPS score, previous
lines of therapy, sensitivity to pre-AHPCT therapy, interval
from diagnosis to AHPCT, and time cohort. Unfortunately, the
presence of chromosomal abnormalities was reported in an
insufﬁcient number of patients to allow inclusion of this
variable in our analysis. We found that compared with the
1995 to 1999 cohort, the risk of death was 23% lower in the
risk of death in the 2000 to 2004 cohort and 32% lower in the
2005 to 2010 cohort. Of note, the other variables associated
with a decreased risk of death were younger age (<50 years),
KPS score 80 to 100, stage <3 disease, only 1 previous line of
therapy, and therapy-responsive disease (Table 4). Similar
improvement in survival in the more recent cohorts was also
conﬁrmed in multivariate analysis in the TED dataset,
including fewer variables but more patients.
Transplantation-Related Mortality
We compared transplantation-related mortality (TRM) at
100 days post-AHPCT to investigate the potential contribu-
tion of better post-transplantation supportive care on OS.different time cohorts. (A) Survival for all registered patients (TED dataset). (B)
splantation. (D) OS after relapse/progression for patients included in the CRF
Table 3
Univariate Analysis for OS, PFS, and Survival after Relapse/Progression
Time after HCT 1995-1999 2000-2004 2005-2010 P, 1995-1999
versus
2000-2004
P, 1995-1999
versus
2005-2010
P, 2000-2004
versus
2005-2010
n at
Risk
Probability
(95% CI)
n at
Risk
Probability
(95% CI)
n at
Risk
Probability
(95% CI)
OS post-AHPCT (TED dataset)
24 mo 1447 0.72 (0.70-0.73) 4449 0.79 (0.78-0.80) 5376 0.84 (0.84-0.85) <.0001 <.0001 <.0001
48 mo 1005 0.54 (0.52-0.56) 2959 0.61 (0.60-0.62) 1799 0.65 (0.64-0.66) <.0001 <.0001 <.0001
60 mo 834 0.47 (0.45-0.49) 2334 0.53 (0.51-0.54) 778 0.56 (0.55-0.58) <.0001 <.0001 .0006
120 mo 329 0.27 (0.25-0.29) 127 0.24 (0.22-0.27) d d .1030 d d
OS post-AHPCT (CRF dataset)
24 mo 465 0.72 (0.69-0.76) 1073 0.81 (0.79-0.83) 1476 0.86 (0.84-0.87) <.0001 <.0001 .0008
48 mo 325 0.54 (0.50-0.58) 689 0.63 (0.60-0.66) 599 0.67 (0.65-0.70) .0004 <.0001 .0171
60 mo 274 0.47 (0.43-0.51) 537 0.55 (0.52-0.58) 278 0.57 (0.54-0.61) .0016 .0001 .2825
120 mo 104 0.28 (0.24-0.32) 47 0.27 (0.23-0.31) d d .7121 d d
PFS post-AHPCT (CRF dataset)
24 mo 314 0.50 (0.46-0.53) 747 0.55 (0.53-0.58) 1011 0.57 (0.55-0.59) .0127 .0006 .2926
48 mo 183 0.31 (0.27-0.34) 392 0.34 (0.31-0.36) 296 0.30 (0.27-0.32) .1856 .6119 d
60 mo 147 0.26 (0.23-0.30) 287 0.27 (0.25-0.30) 127 0.23 (0.21-0.26) .6243 .2469 d
120 mo 44 0.12 (0.09-0.15) 17 0.06 (0.04-0.08) d d d d d
OS postrelapse/progression (CRF dataset)
24 mo 280 0.58 (0.53-0.62) 595 0.65 (0.62-0.68) 636 0.72 (0.69-0.74) .0055 <.0001 .0025
48 mo 139 0.33 (0.29-0.37) 222 0.39 (0.36-0.43) 118 0.40 (0.35-0.43) .0232 .0332 .9911
60 mo 80 0.22 (0.19-0.26) 76 0.24 (0.21-0.28) 16 0.24 (0.18-0.30) .4652 .6210 .9577
120 mo 17 0.10 (0.07-0.14) 4 0.13 (0.08-0.20) d d .5531 d d
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1% to 3%) in the 1995 to 1999 cohort, 2% (95% CI, 1% to 3%) in
the 2000 to 2004 cohort, and 1% (95% CI, 0.6% to 1.3%) in the
2005 to 2010 cohort (P ¼ .90).
PFS and Post-Relapse/Progression Survival
To investigate whether the better survival seen in the
more recent cohorts is correlated with longer post-AHPCT
remissions, we compared PFS after AHPCT among the
cohorts using the CRF dataset. We found a slightly improved
PFS at 24 months for the 2000 to 2004 (55%) and 2005 to
2010 (57%) cohorts compared with the 1995 to 1999 cohort
(50%). This improvement was not detected at later time
points (Table 3 and Figure 2). In contrast, we found improved
survival after relapse/progression at 24 and 48months in the
2000 to 2004 cohort (65% and 39%, respectively) and the
2005 to 2010 cohort (72% and 40%, respectively) compared
with the 1995 to 1999 cohort (58% and 33%, respectively)
(Table 3 and Figure 2).
DISCUSSION
Our data demonstrate the increased use of AHPCT for
early therapy of MM in the United States. In recent years, this
treatment modality is being implemented earlier and typi-
cally after more effective induction regimens than previ-
ously, and there has been a consolidation of single-agent
melphalan as a conditioning regimen. Even though the
availability of novel drugs is a proposed driver of the
increased survival in patients with MM, its impact has not
been distinctly separated from the effect of greater applica-
tion of AHPCT. The present study strongly suggests that
among the patients who undergo AHPCT early in the course
of disease, the exposure to novel drugs is associated with
improved survival, indicating complementary roles of novel
agents and AHPCT in MM management. Because the data
come exclusively from a transplantation registry with no
“no-transplantation” comparator, the present study does not
address the merits of AHPCT in the era of novel therapies.
Initial pivotal trials showing the superiority of conven-
tional therapy plus AHPCT over conventional therapy in MMlimited enrollment to patients age 65 years [22-24]; how-
ever, subsequent series have demonstrated the feasibility of
AHPCT in older patients with MM as well [7,25]. The present
analysis suggests that AHPCT is being offered more fre-
quently to older patients in recent years, extending the
beneﬁts of AHPCT to the age group most frequently affected
by MM. Nonetheless, deﬁnitive proof of better outcomes
with AHPCT thanwithmodern conventional therapy alone in
patients age>65 is still lacking and will require comparisons
with a similar population not pursuing transplantation.
Another relevant demographic aspect of patients
pursuing early AHPCT is the low proportion of African-
American patients. Compared with Caucasians, African-
American individuals have double the incidence of MM
[26], are affected at a younger age [26], and have similar
[27,28] or better [26] outcomes after AHPCT. Nonetheless,
fewer African Americans than expected underwent AHPCT.
The reasons for this discrepancy are unknown, but possible
explanations include referral bias and inadequate access to
transplantation [29].
Our data also show the gradual replacement of melphalan
and prednisone and of vincristine, doxorubicin, and dexa-
methasone as induction therapy by novel, more active drugs.
Consequently, there were a higher proportion of patients
with chemosensitive disease and in complete or partial
remission at the time of AHPCT in the 2005 to 2010 cohort. A
previous study found no association between the type of
induction regimen and post-transplantation outcomes [30];
however, more contemporary trials using more active
induction regimens based on combinations of novel agents
have demonstrated a lasting impact of the induction regimen
on post-transplantation outcomes, with a higher frequency
of patients achieving deeper responses [9-11,31].
Even though we were able to capture the pre-
transplantation therapy for patients reported to the CIBMTR,
we chose to not analyze the impact of speciﬁc drugs or
regimens on survival, but instead used period of diagnosis as
a surrogate. We assumed that patients who were not
exposed to a speciﬁc novel agent before transplantationwere
highly likely to have received the agent at the time of relapse.
Figure 3. OS of patients (from the TED dataset) undergoing early
(<12 months) AHPCT for MM in the 3 different time cohorts and stratiﬁed by
age group: <50 years (A), 50-64 years (B), and 65 years (C). P ¼ .007 for the
independent effects of age and study cohort.
Table 4
Multivariate Analysis for Mortality (CRF Dataset)*
Parameter HR (95% CI) P Value
Period of AHPCT (main effect) 2 df; overall test <.0001
2000-2004 versus 1995-1999 0.77 (0.67-0.89) .0003
2005-2010 versus 1995-1999 0.68 (0.59-0.79) <.0001
2005-2010 versus 2000-2004 0.88 (0.78-0.99) .0340
Age at AHPCT 2 df, overall test <.0001
50-64 versus <50 1.29 (1.13-1.47) .0002
65 versus <50 1.45 (1.23-1.72) <.0001
KPS score 2 df, overall test <.0001
80-100 versus <80 0.59 (0.51-0.70) <.0001
Unknown versus <80 0.57 (0.43-0.76) .0001
DSS/ISS stage III 2 df, overall test <.0001
Yes versus no 1.56 (1.39-1.76) <.0001
Unknown versus no 1.59 (1.29-1.98) <.0001
Lines of chemotherapy 2 df, overall test ¼ .0397
>1 versus 1 1.15 (1.03-1.28) .0116
Unknown versus none 0.96 (0.51-1.80) .8992
Sensitivity to therapy 2 df, overall test ¼ .0004
Sensitive versus resistant 0.76 (0.66-0.87) .0001
Unknown versus resistant 0.45 (0.10-2.05) .3003
*Variables included in the model are time cohort, age at AHPCT, sex, KPS
score, DSS/ISS stage III, number lines of chemotherapy, conditioning
regimen, sensitivity to therapy, and time from diagnosis to AHPCT.
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CIBMTR, thus obscuring our analysis.
Our present analysis clearly indicates improved survival
in patients undergoing early AHPCT for MM in more recent
years. A previous study reported improved survival after
AHPCT in patients withMM for the years 1994-2005, but that
study had a short follow-up period and was not restricted to
patients undergoing AHPCT within the ﬁrst year after diag-
nosis [32]. Possible explanations for the improving survival
in patients undergoing early AHPCT include better patient
selection and improved efﬁcacy of pretransplantation and
post-transplantation therapy. We believe that improved
supportive care has a limited role, given that TRM remained
low in all 3 of our study cohorts.
Our ﬁnding of better postrelapse/progression survival in
the more recent study cohorts, along with the relatively
minor improvement in PFS after AHPCT, strongly suggesta major role for more efﬁcacious postrelapse therapy,
presumably with newer drugs, in the improved OS. In the
CRF dataset, the proportion of patients who underwent
a planned tandem AHPCTwas higher in the third cohort (14%
versus 13% versus 21%), likely reﬂecting new data at the time
[33-35]. The wider use of tandem AHPCT might have
contributed to the improved post-transplantation PFS seen
in this study. The beneﬁt of second AHPCT seems limited to
patients who do not achieve very good partial remissionwith
the ﬁrst transplantation [33,34], a less common event with
the use of modern induction regimens [10-13]. Thus, the role
of tandemAHPCT in the setting of modern induction therapy,
post-transplantation consolidation, and maintenance re-
mains unclear and is currently under investigation.
Recent population-based series have reported improved
survival in patients with newly diagnosed MM. Using
registry data from Sweden, Kristinsson et al. [2] reported
substantially improved survival in patients diagnosed in
1994 to 2003 compared with those diagnosed in previous
years. This improvement was limited to patients age <60
and preceded the broad availability of novel agents, and was
closely associated with a sharp increase in the use of AHPCT.
In a similar study from The Netherlands [4], improved MM
survival was restricted to patients age <65 starting in the
mid-1990s, coinciding with increased use of AHPCT. Finally,
a US study based on the SEER program reported a substan-
tial increase in MM survival in 2002 to 2004 limited to
patients age <70, and most pronounced in those age <50
[1]. More recently, improved outcomes in older patients
with MM has been reported, suggesting a survival impact of
novel drugs in this population, who typically are not treated
with AHPCT [5].
The most important ﬁnding of the present analysis is that
novel therapies are affecting survival even in patients who
undergo early AHPCT, which was previously assumed but not
clearly demonstrated. In the absence of a nontransplantation
comparator cohort, it is impossible to determine whether, in
the era of modern MM therapy, AHPCT can be deferred
during the initial therapy without adversely affecting PFS or
OS. Nonetheless, the veriﬁcation of improved outcomes in
patients undergoing early AHPCT from the incorporation of
L.J. Costa et al. / Biol Blood Marrow Transplant 19 (2013) 1615e1624 1623novel agents in pretransplantation and post-transplantation
management regimens indicates that high-dose melphalan
and new biological agents are complementary, nonredun-
dant therapies. These ﬁndings support the current standard
of care of combining novel drugs and AHPCT in the
management of suitable patients with MM.
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